Trials / Active Not Recruiting
Active Not RecruitingNCT07135349
A Phase II Clinical Study of BW-20507 in Combination With PEG-IFNα for the Treatment of Hepatitis B
A Multi-center, Randomized, Open-label, Phase II Study to Evaluate the Efficacy and Safety of BW-20507 Injection Combined With Pegylated Interferon Alfa in Patients With Chronic Hepatitis B Infection
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 209 (actual)
- Sponsor
- Shanghai Argo Biopharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 16 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized, open-label, multicenter phase II study to evaluate the efficacy and safety of BW-20507 in combination with PEG-IFNα in CHB patients
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BW-20507 with/without NUC | • BW-20507 with/without NUCs will be administrated for 48 weeks |
| DRUG | BW-20507 with/without NUC, Peg-IFNa | • BW-20507 with/without NUC will be administrated for 48 weeks, Peg-IFNa will be administrated. |
Timeline
- Start date
- 2025-09-02
- Primary completion
- 2026-06-07
- Completion
- 2028-05-08
- First posted
- 2025-08-22
- Last updated
- 2026-01-15
Locations
18 sites across 1 country: China
Source: ClinicalTrials.gov record NCT07135349. Inclusion in this directory is not an endorsement.